Axsome Therapeutics IncNASDAQ:AXSM
- LAST PRICE75.0100
- TODAY'S CHANGE (%)-0.9300 (-1.2247%)
- Bid / Lots74.9500/ 1
- Ask / Lots75.0700/ 1
- Open / Previous Close75.5800 / 75.9400
- Day Range
- 52 Week Range
- Volume148,106
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AXSM |
|---|---|---|
| 09:32 ET | 14168 | 74.54 |
| 09:34 ET | 1174 | 75.25 |
| 09:36 ET | 305 | 75.28 |
| 09:38 ET | 358 | 74.86 |
| 09:39 ET | 3360 | 74.57 |
| 09:41 ET | 500 | 75.37 |
| 09:43 ET | 2288 | 74.965 |
| 09:45 ET | 1295 | 74.935 |
| 09:48 ET | 2695 | 75.045 |
| 09:50 ET | 824 | 74.56 |
| 09:52 ET | 4094 | 75.145 |
| 09:54 ET | 3060 | 75.075 |
| 09:56 ET | 1803 | 75.44 |
| 09:57 ET | 3516 | 74.78 |
| 09:59 ET | 800 | 75.065 |
| 10:01 ET | 1225 | 74.55 |
| 10:03 ET | 1000 | 74.61 |
| 10:06 ET | 1162 | 74.705 |
| 10:10 ET | 4803 | 75.05 |
| 10:12 ET | 6771 | 74.84 |
| 10:14 ET | 6212 | 74.465 |
| 10:15 ET | 3000 | 73.89 |
| 10:17 ET | 2355 | 74 |
| 10:19 ET | 1600 | 73.69 |
| 10:21 ET | 485 | 73.72 |
| 10:24 ET | 3026 | 73.66 |
| 10:26 ET | 2975 | 74.15 |
| 10:28 ET | 700 | 74.17 |
| 10:30 ET | 1200 | 74 |
| 10:32 ET | 14018 | 74.66 |
| 10:33 ET | 733 | 74.535 |
| 10:35 ET | 1010 | 74.61 |
| 10:37 ET | 500 | 74.61 |
| 10:39 ET | 300 | 74.59 |
| 10:42 ET | 300 | 74.565 |
| 10:44 ET | 1443 | 74.645 |
| 10:46 ET | 200 | 74.575 |
| 10:48 ET | 200 | 74.575 |
| 10:50 ET | 325 | 74.565 |
| 10:51 ET | 1005 | 74.73 |
| 10:53 ET | 300 | 74.81 |
| 10:55 ET | 100 | 74.94 |
| 10:57 ET | 1200 | 74.87 |
| 11:00 ET | 1011 | 74.815 |
| 11:02 ET | 700 | 75.11 |
| 11:04 ET | 900 | 75.06 |
| 11:06 ET | 425 | 75.11 |
| 11:08 ET | 562 | 75.135 |
| 11:09 ET | 306 | 75.14 |
| 11:11 ET | 250 | 75.12 |
| 11:13 ET | 100 | 75.115 |
| 11:15 ET | 1050 | 75.09 |
| 11:18 ET | 300 | 75.095 |
| 11:20 ET | 711 | 75.08 |
| 11:22 ET | 3263 | 75.01 |
Today
Yesterday
*DJ Axsome Therapeutics 1Q Loss/Shr $1.44 >AXSM, from 7:00AM ET on Monday May 06, 2024 by Dow Jones
7:00AM ET on Monday May 06, 2024 by Dow JonesAxsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update, from 7:00AM ET on Monday May 06, 2024 by Dow Jones
7:00AM ET on Monday May 06, 2024 by Dow Jones
May 1, 2024
Axsome Therapeutics Recognizes May as Mental Health Awareness Month, from 7:00AM ET on Wednesday May 01, 2024 by Dow Jones
7:00AM ET on Wednesday May 01, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Axsome Therapeutics Inc | 3.6B | -11.7x | --- |
Insmed Inc | 3.9B | -4.9x | --- |
Arrowhead Pharmaceuticals Inc | 3.1B | -9.1x | --- |
MorphoSys AG | 2.7B | -5.3x | --- |
Ultragenyx Pharmaceutical Inc | 3.6B | -5.3x | --- |
Twist Bioscience Corp | 2.6B | -13.1x | --- |
Company Information
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Contact Information
- Headquarters
- One World Trade Center, 22Nd FloorNEW YORK, NY, United States 10007
- Phone
- 212-332-3241
- Fax
- 212-320-0245
Executives
- Chairman of the Board, President, Chief Executive Officer, Founder
- Herriot Tabuteau
- Chief Financial Officer
- Nick Pizzie
- Chief Operating Officer
- Mark Jacobson
- Executive Vice President - Commercial and Business Development
- Lori Englebert
- General Counsel
- Hunter Murdock
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6B |
|---|---|
Revenue (TTM) | $251.0M |
Shares Outstanding | 47.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.27 |
EPS | $-6.38 |
Book Value | $4.03 |
P/E Ratio | -11.7x |
Price/Sales (TTM) | 14.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -116.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
